Studies found that breast cancer-related mutations of genes, including PIK3CA, TP53, ESR1, and ERBB2, can serve as biomarkers and facilitate a personalized treatment for breast cancer patients [4–7]. Here, ERBB2 is linked to breast carcinoma.